749269-73-6

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carbonitrile is used as a building block for the synthesis of more complex molecules, particularly in the pharmaceutical sector. Its unique structure allows for the creation of a variety of compounds with potential therapeutic applications.
Used in Chemical Research and Development:
In the field of chemical research and development, 1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carbonitrile is employed as a key intermediate in the synthesis of novel chemical entities. Its reactivity and structural features make it a valuable component in the development of new materials and compounds.
Safety Considerations:
Due to its reactive nature, safety precautions must be strictly followed when handling 1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carbonitrile to prevent any adverse reactions or hazards. Proper protective measures and adherence to safety protocols are essential when working with 1-(4-BroMo-3-fluorophenyl)cyclopropane-1-carbonitrile in a laboratory setting.

Upstream product

• 222978-01-0 4-bromo-3-fluorobenzyl alcohol 
• 1240286-88-7 4-Bromo-3-fluorobenzyl methanesulfonate 
• 499983-13-0 2-( 4-bromo-3-fluorophenyl)acetonitrile 
• 96-49-1 [1,3]-dioxolan-2-one 
• 1072-53-3 ethyleneglycol sulfate 
• 107-04-0 1-Bromo-2-chloroethane 
• 452-74-4 4-bromo-3-fluorotoluene 
• 127425-73-4 1-bromo-4-(bromomethyl)-2-fluorobenzene 
• 106-93-4 ethylene dibromide 

Downstream Products

• 884905-30-0 1-(3-fluoro-4-iodophenyl)cyclopropanecarboxylic acid 
• 865360-50-5 1-(4'-bromo-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid 
• 749269-83-8 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid 
• 865360-51-6 1-(4'-bromo-2,3'-difluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid 
• 917397-94-5 1-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropanecarbonitrile 
• 1279100-92-3 2-bromoethyl 1-(2-fluorobiphenyl-4-yl)cyclopropanecarboxylate 
• 1279100-93-4 2-bromoethyl 1-(2-fluoro-4'-(trifluoromethyl)biphenyl-4-yl)cyclopropanecarboxylate 
• 1279100-97-8 2-bromoethyl 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylate 
• 1279100-99-0 2-(nitrooxy)ethyl 1-(2-fluorobiphenyl-4-yl)cyclopropanecarboxylate 
• 1279101-03-9 2-(nitrooxy)ethyl 1-(2-fluoro-4'-(trifluoromethyl)biphenyl-4-yl)cyclopropanecarboxylate 
• 1279101-06-2 2-(nitrooxy)ethyl 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylate 

Relevant academic research and scientific papers

Inhibitor for AKR1C3 or pharmaceutically acceptable salt of inhibitor as well as preparation method and application of inhibitor or pharmaceutically acceptable salt

The invention discloses an inhibitor for AKR1C3 or a pharmaceutically acceptable salt of the inhibitor as well as a preparation method and application of the inhibitor or the pharmaceutically acceptable salt. Non-steroidal anti-inflammatory drug flurbiprofen is used as a lead compound for structural optimization. The invention discloses the biphenyl-based AKR1C3 inhibitor represented by a formula(I) shown in the specification and the preparation method of the inhibitor. Target activity tests prove that the compounds provided by the invention can significantly inhibit activity of AKR1C3, and can be further used for development of a drug for treating and/or preventing diseases by inhibiting the aldo-keto reductase AKR1C3; and a molecular basis is laid for drug resistance-related mechanisticstudy of tumors.

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

Efficient cyclopropanation of aryl/heteroaryl acetates and acetonitriles with vinyl diphenyl sulfonium triflate

A convenient method was developed for the cyclopropanation of aryl acetates and aryl acetonitrile using vinyl diphenyl sulfonium triflate salt. The newly developed conditions are simple, mild, and compatible with a wide range of functional groups, without the need to apply an inert atmosphere, or alkali bases.

Cyclopropanation of substituted phenylacetonitriles or phenyl acetates

The present invention relates to a process for the cyclopropanation with ethylene carbonate or ethylene sulfate of a compound of formula (II): wherein G is -CN or -COOR in which R is a C1-C4 straight or branched alkyl X and Y are independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, R1O- and R1S- wherein R1 is C1-C4 straight or branched alkyl chain.

PROCESS FOR THE PREPARATION OF DERIVATIVES OF 1-(2-FLUORO[1,1'-BIPHENYL]-4-YL)-CYCLOPROPANECARBOXYLIC ACID

The present invention relates to a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R represents one or more groups independently selected from fluorine, chlorine, bromine, and iodine, said process comprising the cyclopropanation of a compound of formula (II) with ethylene carbonate or ethylene sulfate: wherein X is chlorine, bromine, iodine or a triflate group (CF3SO3) or a group ?wherein R is as defined above and G is —CN or —COOR2 wherein R2 is a C1-C4 straight or branched alkyl chain.

IMPROVED PROCESS FOR THE PREPARATION OF DERIVATIVES OF 1-(2-FLUORO[1,1'-BIPHENYL]-4-YL)-CYCLOPROPANECARBOXYLIC ACID

The present invention relates to a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof: formula (I) wherein R represents one or more groups independently selected from fluorine, chlorine, bromine, and iodine, said process comprising the cyclopropanation of a compound of formula (II) with ethylene carbonate or ethylene sulfate: formula (II) wherein X is chlorine, bromine, iodine or a triflate group (CF3SO3) or a group (formula) wherein R is as defined above and G is -CN or -COOR2 wherein R2 is a C1-C4 straight or branched alkyl chain.

TETRAHYDROTHIAZEPINE DERIVATIVE

The present invention relates to a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof having an excellent effect of inhibiting 11β-hydroxysteroid dehydrogenase type 1: General formula (I) wherein R1 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from substituent group A or a heterocyclic group that may be substituted with 1 to 4 group(s) independently selected from substituent group A; R2 independently represents a halogen atom or a C1-C6 alkyl group; n represents an integer of 0 to 2; and substituent group A represents the group consisting of halogen atoms, C1-C6 alkyl groups, and so forth.

PROCESS FOR THE PREPARATION OF DERIVATIVES OF 1-(2-HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID

The invention relates to a process for the preparation of a compound of formula (IA).

PROCESS FOR THE PREPARATION OF DERIVATIVES OF 1-(2- HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID

Compounds according to formula (IA): may be efficiently prepared by the disclosed process.

Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates

Poor blood-brain barrier penetration of nonsteroidal anti-inflammatory drugs (NSAIDs) has been blamed for the failure of the selective amyloid lowering agent (SALA) R-flurbiprofen in phase 3 clinical trials for Alzheimer's disease (AD). NO-donor NSAIDs (NO-NSAIDs) provide an alternative, gastric-sparing approach to NSAID SALAs, which may improve bioavailability. NSAID analogues were studied for anti-inflammatory activity and for SALA activity in N2a neuronal cells transfected with human amyloid precursor protein (APP). Flurbiprofen (1) analogues were obtained with enhanced anti-inflammatory and antiamyloidogenic properties compared to 1, however, esterification led to elevated A 1-42 levels. Hybrid nitrate prodrugs possessed superior anti-inflammatory activity and reduced toxicity relative to the parent NSAIDs, including clinical candidate CHF5074. Although hybrid nitrates elevated A 1-42 at higher concentration, SALA activity was observed at low concentrations (1 μM): both A1-42 and the ratio of A 42/A1-40 were lowered. This biphasic SALA activity was attributed to the intact nitrate drug. For several compounds, the selective modulation of amyloidogenesis was tested using an immunoprecipitation MALDI-TOF approach. These data support the development of NO-NSAIDs as an alternative approach toward a clinically useful SALA.